PRODUCT AT A GLANCE
- Cardea SOLO helps to increase AFib detection rate and patient outcomes by reducing strokes in your patient population with early detection of AFib.
- 7 day ECG monitoring demonstrates 96.6% diagnostic yield for arrhythmia whereas 71.1% from 2-day monitoring.
- More specifically, Cardea SOLO’s unique algorithm has greater than 98.7% positive predictive value (PPV) and 96.7% sensitivity recognizing AFib and flutter
SPECIFICATIONS
